PP
JNCE

PDT Partners’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

PDT Partners’s Portfolio JNCE Stock Details JNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-15,009
Closed -$102K – 955
2021
Q2 		$102K Buy
15,009
+2,674
+22% +$22.2K 0.01% 763
2021
Q1 		$127K Buy
+12,335
New +$135K 0.01% 728
2020
Q2 		– Sell
-61,968
Closed -$294K – 865
2020
Q1 		$294K Buy
61,968
+48,700
+367% +$280K 0.02% 481
2019
Q4 		$116K Sell
13,268
-13,632
-51% -$73.7K 0.01% 684
2019
Q3 		$90K Sell
26,900
-3,800
-12% -$15.2K 0.01% 439
2019
Q2 		$152K Sell
30,700
-12,412
-29% -$65.9K 0.01% 388
2019
Q1 		$267K Buy
+43,112
New +$208K 0.02% 366

Other funds holding JNCE

PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
TGI
TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

PDT Partners's JNCE Position: Q3 2021 in Review

PDT Partners sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q3 2021, closing a stake of 15,009 shares — an estimated $102K sold.

PDT Partners first reported a position in JNCE in Q1 2019 and held it in 7 quarters. The position peaked at $294K in Q1 2020. 115 funds tracked by Wall St. Rank hold JNCE as of Q3 2021.

  • PDT Partners reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • PDT Partners sold 15,009 Jounce Therapeutics, Inc. Common Stock shares in Q3 2021, an estimated $102K.
  • PDT Partners first reported a position in Jounce Therapeutics, Inc. Common Stock in Q1 2019 and held it in 7 quarters.
  • PDT Partners's Jounce Therapeutics, Inc. Common Stock position peaked at $294K in Q1 2020.
  • 115 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q3 2021.

Based on PDT Partners's 13F filing for Q3 2021, filed 15 Nov 2021.